ITM Isotope Technologies Munich SE has appointed Annette Breunig as chief people officer, the company announced Oct. 13.
Breunig, who has more than 25 years of HR leadership experience, joins the Germany-based radiopharmaceutical firm from Infios Group, where she served as executive vice-president of people and culture. She has also held senior HR roles at Siemens, Sanofi, and Körber Group.
According to ITM, Breunig will lead global human resources strategy, strengthen company culture, and support the firm’s long-term growth.
Focus on organizational development
Breunig will oversee the HR team as ITM continues to expand its workforce to support operations in cancer treatment research and development.
“Annette’s dedication to supporting top-performing teams at global, high-growth companies has created dynamic work environments,” said Dr. Andrew Cavey, CEO of ITM. “As ITM continues scaling its organization to meet the needs of people living with cancer, her leadership will be a great addition.”
Cavey added that employees “are the core that drive [ITM’s] success” and said the appointment strengthens the company’s HR capacity to “ensure that ITM remains a great place to work.”
Extensive HR background
Before joining ITM, Breunig led global workforce integration efforts at Infios Group across 10 countries in Asia, Europe, and the U.S. At Körber Supply Chain and Körber Pharma, she established global HR teams and implemented international people strategies.
Her decade at Siemens included oversight of talent development systems and compensation policies. Earlier in her career, she held HR management roles at Aventis—later acquired by Sanofi—where she helped design benefit plans across multiple regions.
Breunig holds a business degree from Julius Maximilians University in Würzburg, Germany, and is a certified business coach.
“ITM’s evolution into a global radiopharmaceutical leader is a true growth story, driven by innovation and the passion of its people,” Breunig said. “I was drawn to ITM’s clear purpose—improving outcomes for people with cancer—and I look forward to working with this dynamic team to support its continued growth and global success.”
About ITM
Founded in Munich, ITM develops and manufactures radiopharmaceutical diagnostics and therapeutics for hard-to-treat cancers. The company operates globally and has several precision oncology programs in late-stage clinical development.
